p.107 抽出テキスト

917. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA 2016;315:2683–93. https://doi.org/10.1001/jama.2016.7635 918. Vitale C, Berthelot E, Coats AJS, Loreena H, Albert NM, Tkaczyszyn M, et al. Assessment of frailty in patients with heart failure: a new Heart Failure Frailty Score developed by Delphi consensus. ESC Heart Fail 2025;12:1818–31. https://doi.org/10.1002/ehf2.15187 919. Villaschi A, Chiarito M, Pagnesi M, Stolfo D, Baldetti L, Lombardi CM, et al. Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: insights from the HELP-HF registry. Eur J Heart Fail 2024;26:1399–407. https://doi.org/10.1002/ejhf.3234 920. Somech J, Joshi A, Mancini R, Chetrit J, Michel C, Sheppard R, et al. Comparison of questionnaire and performance-based physical frailty scales to predict survival and health-related quality of life in patients with heart failure. J Am Heart Assoc 2023;12:e026951. https://doi.org/10.1161/JAHA. 122.026951 921. Uchmanowicz I, Lee CS, Vitale C, Manulik S, Denfeld QE, Uchmanowicz B, et al. Frailty and the risk of all-cause mortality and hospitalization in chronic heart failure: a meta-analysis. ESC Heart Fail 2020;7:3427–37. https://doi. org/10.1002/ehf2.12827 922. Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 2019;21:1299–305. https://doi. org/10.1002/ejhf.1611 923. Yang X, Lupon J, Vidan MT, Ferguson C, Gastelurrutia P, Newton PJ, et al. Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta-analysis. J Am Heart Assoc 2018;7:e008251. https://doi.org/10.1161/JAHA.117.008251 924. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10.1093/eurjpc/zwaa167 925. Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, et al. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail 2018;20:295–303. https://doi.org/10.1002/ejhf.901 926. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 2016;4:464–72. https://doi.org/ 10.1016/j.jchf.2016.02.017 927. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264–74. https://doi. org/10.1001/jama.2014.18229 928. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail 2020;22:957–66. https://doi.org/10.1002/ejhf.1871 929. Rey JR, Caro-Codon J, Rosillo SO, Iniesta AM, Castrejon-Castrejon S, Marco-Clement I, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail 2020;22:2205–15. https://doi.org/10.1002/ejhf.1990 930. Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, et al. Clinical outcomes in patients with heart failure hospitalized with COVID-19. JACC Heart Fail 2021;9:65–73. https://doi.org/10. 1016/j.jchf.2020.11.003 931. Gotsman I, Shuvy M, Tahiroglu I, Zwas DR, Keren A. Influenza vaccination and outcome in heart failure. Am J Cardiol 2020;128:134–39. https://doi. org/10.1016/j.amjcard.2020.05.019 932. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et al. Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. JACC Heart Fail 2016;4:152–58. https://doi.org/10.1016/j.jchf.2015.10.012 933. Modin D, Jorgensen ME, Gislason G, Jensen JS, Kober L, Claggett B, et al. Influenza vaccine in heart failure. Circulation 2019;139:575–86. https://doi. org/10.1161/CIRCULATIONAHA.118.036788 934. Anderson CS, Hua C, Wang Z, Wang C, Jiang C, Liu R, et al. Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China. Lancet 2025;406:1020–31. https://doi.org/10.1016/S0140- 6736(25)01485-0 935. Heidecker B, Libby P, Vassiliou VS, Roubille F, Vardeny O, Hassager C, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. Eur Heart J 2025;46:3518–31. https://doi.org/10.1093/eurheartj/ehaf384 936. Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, et al. Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. Lancet Glob Health 2022;10:e1835–44. https://doi.org/10.1016/S2214- 109X(22)00432-6 937. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017;14:39–55. https:// doi.org/10.1038/nrcardio.2016.174 938. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126:1040–49. https://doi.org/10.1161/CIRCULATIONAHA.112.096024 939. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA 2018;320:1349–59. https://doi. org/10.1001/jama.2018.13770 940. Peeters RP. Subclinical hypothyroidism. N Engl J Med 2017;376:2556–65. https://doi.org/10.1056/NEJMcp1611144 941. Peng CC, Huang HK, Wu BB, Chang RH, Tu YK, Munir KM. Association of thyroid hormone therapy with mortality in subclinical hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol Metab 2021;106: 292–303. https://doi.org/10.1210/clinem/dgaa777 942. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008;10:1102–07. https://doi.org/10.1016/j. ejheart.2008.07.013 943. Borghi C, Palazzuoli A, Landolfo M, Cosentino E. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. Heart Fail Rev 2020;25:43–51. https://doi.org/10.1007/s10741-019-09869-z 944. Borghi C, Tykarski A, Widecka K, Filipiak KJ, Domienik-Karlowicz J, Kostka-Jeziorny K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25:545–63. https://doi.org/10.5603/CJ.2018.0116 945. Borghi C, Domienik-Karlowicz J, Tykarski A, Widecka K, Filipiak KJ, Jaguszewski MJ, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J 2021;28:1–14. https://doi.org/10.5603/CJ.a2021.0001 946. Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. https://doi.org/10.1136/bmj.i4857 947. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92:1610–15. https://doi.org/10.1136/hrt.2005.082388 948. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–56. https://doi.org/10.1016/S0140-6736(04)16299-5 949. Jaarsma T. Sexual function of patients with heart failure: facts and numbers. ESC Heart Fail 2017;4:3–7. https://doi.org/10.1002/ehf2.12108 950. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006;48:1111–19. https://doi.org/10.1016/j.jacc.2006.05.052 951. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall’Armi V, Badagliacca R, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 2014;12:185. https://doi.org/10.1186/s12916-014-0185-3 952. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2024;83:417–26. https:// doi.org/10.1016/j.jacc.2023.10.041 953. Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026